Several small pilot studies have been done by Dr. Paul Cheney (working in collaboration with Professor Ruggiero) and Professor Ruggiero himself. Dr. Cheney presented his one-month study of MAF 314 at the 2011 IAMECFS conference in Ottawa. Professor Ruggiero presented additional information in Padua a month later. There have been no additional published studies of MAF 314 since then.
In answer to a question in Ottawa about MAF 314, Dr. Cheney answered, "It works." For the past year, Dr. Cheney has used MAF 314 in his practice with selected patients. He is a true champion of this therapy. He follows his selected patients closely with various tests, including Nagalase and 1,25 dihydroxy vitamin D. Dr. Cheney has far and away the most clinical experience with MAF 314 and his continuing contributions in refining this treatment are available to his patients, as well as to subscribers to his research website. It is recommended that both MAF 314 and GcMAF be used under a doctor's supervision.
Dr. Derek Enlander in NYC has made his own version of a MAF-like substance called MAF 878. Anecdotal reports are that MAF 878 has a positive effect on patients with very few side effects.
MAF 314 was developed as an alternative to injectable GcMAF. Injectable GcMAF, as developed by Professor Nobuto Yamamoto, is seen as an adjunct therapy for HIV and various cancers. Small trials by Professor Yamamoto have not been expanded upon by others for unknown reasons. More recently injectable or chemical GcMAF has been used in patients with ME/CFS, primarily by Dr. Kenny De Meirleir, Dr. Paul Cheney and Dr. Derek Enlander. Dr. Enlander has indicated publicly that GcMAF is the best therapy for ME/CFS in the last ten years. Improvement has also been seen in these patient groups. There is a fine presentation by Dr. De Meirleir on GcMAF from a conference at Mt. Sinai ME/CFS center in late 2011. It can be viewed here.
I have written about MAF 314 in another post. It is my experience and the experience of others that MAF 314 strengthens the immune system - in unknown ways. Patients report feeling stronger on MAF 314 and MAF 878. The mechanism might be as simple as MAF operating as a super probiotic and stabilizing and improving the gut ecology. It seems to take some months before positive benefits are felt. It is unclear whether MAF 314 raises NK cell function, but that would certainly be an important benchmark for ME/CFS patients. This certainly might be a worthwhile study: Does GcMAF and MAF 314 have effects on NK cell functionality (LU 30)?
We in the ME/CFS community welcome this informative video interview of Professor Ruggiero and appreciate his research work in ME/CFS. His work in this field has continued with MAF 314 and expanded with significant research in other areas of ME/CFS. I will write about this soon.
This video interview with Professor Ruggiero was made by Peter Cairns in Professor Ruggiero's office in Florence earlier this year.